title: Patients' compliance with different administration routes for allergen immunotherapy in Germany.
abstract: BACKGROUND
  Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural course of allergic diseases. According to AIT guidelines and summary of product characteristics (SmPCs), the treatment should be carried out for at least 3 years. It is controversially discussed whether subcutaneous or sublingual administration routes cause higher patients' compliance.
  
  
  METHODS
  German sales data for different preparations of the allergen manufacturer Allergopharma GmbH & Co. KG were retrospectively evaluated for 5 consecutive years, based on prescriptions per patient: pollen sublingual immunotherapy (SLIT) and high-dose hypoallergenic (allergoid) or unmodified depot pollen and mite preparations for subcutaneous immunotherapy (SCIT). To identify patients' compliance, "completed treatment years" were determined. A completed treatment year was defined by the required number of prescribed allergen preparations according to the recommended dosage scheme given in the respective SmPCs.
  
  
  RESULTS
  Prescription data of 85,241 patients receiving pollen or mite SCIT and 706 patients receiving pollen SLIT were included in this analysis. Patients' compliance for at least 3 treatment years with high-dose hypoallergenic pollen SCIT was higher when administered perennially (60%) compared to preseasonally (27%). Prescriptions for at least 3 years were received from 42% of patients with pollen SCIT and from 45% of patients with mite SCIT. Compliance with SLIT was lowest with only 16% of patients receiving prescriptions for at least 3 treatment years. Children and adolescents were more compliant than adults, independent of whether they received SLIT or SCIT.
  
  
  CONCLUSIONS
  In general, patients' compliance with SCIT using high-dose hypoallergenic or unmodified depot preparations was higher than with pollen SLIT. Perennial application of SCIT seems to increase compliance in comparison to the preseasonal application. Children and adolescents were most compliant, independent of the preparation applied.
authors.affiliation: Allergopharma GmbH & Co. KG, Reinbek, Germany.
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Egert-Schmidt
authors.affiliation: Allergopharma GmbH & Co. KG, Reinbek, Germany.
authors.forename: Jan-Marcel
authors.initials: JM
authors.lastname: Kolbe
authors.affiliation: Allergopharma GmbH & Co. KG, Reinbek, Germany.
authors.forename: Sabine
authors.initials: S
authors.lastname: Mussler
authors.affiliation: Allergopharma GmbH & Co. KG, Reinbek, Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Thum-Oltmer
keywords: compliance; high-dose hypoallergenic preparation; perennial immunotherapy; preseasonal immunotherapy; real-life data; subcutaneous immunotherapy; sublingual immunotherapy